NCT04557085View on ClinicalTrials.gov

Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS

PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

540

Participants

Timeline

Start Date

March 8, 2021

Primary Completion Date

February 29, 2024

Study Completion Date

March 31, 2025

Conditions

Partial SeizureFocal Seizure

Interventions

DRUG

Cenobamate

Cenobamate tablets

DRUG

Placebo

Matching placebo tablets

Trial Locations (3)

Unknown

Site 3, Shanghai

Site 2, Tokyo

Site 1, Seoul

All Listed Sponsors

lead

SK Life Science, Inc.

INDUSTRY

NCT04557085 - Randomized, Double-blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Therapy in POS | Biotech Hunter | Biotech Hunter